CMS has announced the first 10 prescription drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, which is estimated to account for one-fifth of the program's total spending. This shift from the current system, which has been barred from negotiating drug costs, is expected to have a positive impact on the cost of prescription drugs for the 65 million people in the US covered by Medicare.
